Clinical and Experimental Hepatology最新文献

{"title":"Significant roles of potential genes and their mutations in nonalcoholic fatty liver disease.","authors":"Babak Sokouti","doi":"10.5114/ceh.2023.128633","DOIUrl":"https://doi.org/10.5114/ceh.2023.128633","url":null,"abstract":"<p><p>In addition to having inflammation in the liver, overweight people also have changes in the composition of their immune systems and subsets of their immune systems. There are several genes involved in liver metabolism that have been implicated in nonalcoholic fatty liver disease (NAFLD), a liver disease associated with obesity, which is caused by high triglycerides and liver transaminases. NAFLD, a global liver disease, may differ in gene expression depending on where a person lives. In some alleles, the risk factors were independent. Finally, the researchers identified many genetic variations connected to fatty liver disease in those who did not drink alcohol regularly. These variants were located in genes involved in RNA metabolism, protein catabolism, and energy metabolism.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 2","pages":"95-105"},"PeriodicalIF":1.5,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b7/2d/CEH-9-50841.PMC10369655.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9942032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of serum CXCL9 and pentraxin 3 as novel markers for hepatocellular carcinoma in cirrhotic hepatitis C patients.","authors":"Rafik Gabbour Mehanna,&nbsp;Khaled Mohiedeen,&nbsp;Mohamed Kassem,&nbsp;Akram Deghady,&nbsp;Hossam Abouelkheir","doi":"10.5114/ceh.2023.125255","DOIUrl":"https://doi.org/10.5114/ceh.2023.125255","url":null,"abstract":"<p><strong>Aim of the study: </strong>Hepatocellular carcinoma (HCC) is the most frequent primary cancer of the liver. It is also one of the world's most common cancers and an important leading cause of cancer mortality in many parts of the world. As a result, it is essential to look for efficient markers for early and accurate HCC diagnosis. CXCL9 and pentraxin 3 are involved in the pathway of many cancers. The aim of the study was to assess the value of serum CXCL9 and pentraxin 3 as diagnostic markers of HCC among cirrhotic hepatitis C virus (HCV) patients.</p><p><strong>Material and methods: </strong>The current study was conducted on 90 candidates divided into 3 groups: group I - 30 patients with HCV induced liver cirrhosis without HCC; group II - 30 patients with HCV induced liver cirrhosis with HCC; group III - 30 healthy subjects (control group). All candidates were subjected to detailed history taking and thorough clinical examination, laboratory investigations, serum CXCL9, serum pentraxin 3, ultrasound abdomen and CT triphasic liver in group III.</p><p><strong>Results: </strong>Serum CXCL9 and serum pentraxin 3 levels were significantly higher in group II than group I and significantly higher in group I than group III.</p><p><strong>Conclusions: </strong>Serum CXCL9 and serum pentraxin 3 could be utilized as diagnostic markers for HCC.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"14-20"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/21/59/CEH-9-50173.PMC10090998.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317881","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cirrhosis-induced oxidative stress in erythrocytes: The therapeutic potential of taurine.","authors":"Hossein Niknahad,&nbsp;Pooria Sayar Mehrabani,&nbsp;Abdollah Arjmand,&nbsp;Sepideh Alidaee,&nbsp;Sahra Mazloomi,&nbsp;Parinaz Ahmadi,&nbsp;Narges Abdoli,&nbsp;Mohsen Saeed,&nbsp;Mohammad Rezaei,&nbsp;Mohammad Mehdi Ommati,&nbsp;Reza Heidari","doi":"10.5114/ceh.2023.126028","DOIUrl":"https://doi.org/10.5114/ceh.2023.126028","url":null,"abstract":"<p><strong>Aim of the study: </strong>Cholestasis/cirrhosis could induce erythrocyte lysis. The incidence of various types of anemia in cirrhosis is approx. 75%. Several studies have mentioned the pivotal role of oxidative stress in this complication. Taurine (TAU) is the human body's most abundant free amino acid. TAU is known as a robust cell membrane stabilizer. Many studies have mentioned that TAU could counteract oxidative stress in various experimental models. The current study was intended to evaluate the effect of TAU on erythrocytes in cirrhotic rats.</p><p><strong>Material and methods: </strong>Bile duct ligation (BDL) surgery was carried out on rats. Then, complete blood count (CBC), hemoglobin (Hgb), hematocrit (HTC), and erythrocytes' G6PD, catalase (CAT), and superoxide dismutase (SOD) activity were measured. Moreover, biomarkers of oxidative stress were assessed, and the erythrocytes' morphological changes were monitored in the cirrhotic mice exposed to TAU (0.25%, 0.5%, and 1% w : v in drinking water).</p><p><strong>Results: </strong>Significant changes in the assessed erythrocyte parameters (G6PD activity, Hgb, HTC, and erythrocyte count) and red blood cells (RBC) morphological alterations were detected on day 42 after BDL surgery. Biomarkers of oxidative stress also did not change at the time points, except on post-BDL days 28 and 42. A significant decrease in blood parameters was evident at post-BDL day 42. All doses of TAU (0.25%, 0.5%, and 1% w : v in drinking water) significantly improved erythrocyte parameters and encountered oxidative stress in the erythrocytes of cirrhotic animals.</p><p><strong>Conclusions: </strong>These data indicate that TAU could be a safe agent to mitigate cirrhosis-induced erythrocyte damage and anemia. Further investigations are necessary to prove this in clinical settings.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"79-93"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ed/ab/CEH-9-50386.PMC10090995.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recommendations of the Polish Group of Experts for HCV for the treatment of hepatitis C in 2023.","authors":"Krzysztof Tomasiewicz,&nbsp;Robert Flisiak,&nbsp;Jerzy Jaroszewicz,&nbsp;Piotr Małkowski,&nbsp;Małgorzata Pawłowska,&nbsp;Anna Piekarska,&nbsp;Krzysztof Simon,&nbsp;Dorota Zarębska-Michaluk","doi":"10.5114/ceh.2023.125957","DOIUrl":"https://doi.org/10.5114/ceh.2023.125957","url":null,"abstract":"<p><p>The recommendations define the principles of diagnosis and treatment of hepatitis C virus (HCV) infection according to the latest knowledge. The main goal of the treatment of HCV infection is to eliminate the virus from the body, which in turn leads to stopping the progression or causes the regression of previously formed changes in the liver. The current version of the guidelines prioritizes pangenotypic regimens and includes guidelines for special patient populations such as children, patients with cirrhosis, human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection, patients with renal failure, liver failure and lack of response to previous therapies as well as patients in the peri-transplant period.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"1-8"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/f6/62/CEH-9-50360.PMC10090994.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of efficacy and safety of endoscopic and radiological interventions for gastric varices: A systematic review and network meta-analysis.","authors":"Suprabhat Giri,&nbsp;Vaneet Jearth,&nbsp;Vishal Seth,&nbsp;Harish Darak,&nbsp;Sridhar Sundaram","doi":"10.5114/ceh.2023.126077","DOIUrl":"https://doi.org/10.5114/ceh.2023.126077","url":null,"abstract":"<p><strong>Aim of the study: </strong>There is a paradigm shift in the management of gastric varices with the availability of endoscopic ultrasound and radiologic interventions. The optimal choice of intervention remains a dilemma for most treating physicians.</p><p><strong>Material and methods: </strong>We searched MEDLINE, the Cochrane Central Register of Controlled Trials, and ScienceDirect for studies comparing endoscopic glue injection, endoscopic thrombin injection (THB), variceal band ligation, EUS-guided coiling, EUS-guided glue injection, EUS-guided coiling with glue (EUS-C+G), balloon occluded retrograde transvenous obliteration (BRTO), and transjugular intrahepatic portosystemic shunt (TIPS) for gastric varices in adults. The data on four outcomes - obliteration of varices, rebleeding, adverse effects, and mortality - were pooled using a random-effects model. Treatment estimates were calculated as odds ratios (ORs) along with their 95% confidence interval (CI). The relative ranking of interventions for various outcomes was calculated as their surface under the cumulative ranking curve (SUCRA).</p><p><strong>Results: </strong>We identified 34 studies (10 randomized controlled trials, 24 non-randomized trials) with 2783 patients. Based on SUCRA plots, BRTO (SUCRA 95.1) had the highest rate of variceal obliteration followed by EUS-C+G (SUCRA 80.9). The risk of rebleeding was lowest with BRTO (SUCRA 85.1) followed by EUS-C+G (SUCRA 78.8). Moderate-severe adverse effects were least likely with THB (SUCRA 92.5) and highest with TIPS (SUCRA 3.7). In terms of mortality, EUS-C+G (73.5) had the lowest probability of overall mortality followed by TIPS (69.1).</p><p><strong>Conclusions: </strong>In this network meta-analysis, we found BRTO and EUS-guided therapies to be superior to endoscopic glue injection. However, the level of evidence remains low.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"57-70"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/09/35/CEH-9-50402.PMC10090989.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317887","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Genetic profile of MIF single nucleotide polymorphism (rs755622 G>C) in hepatocellular carcinoma among Egyptian patients.","authors":"Heba Ahmed Osman,&nbsp;Marwa El-Sayed,&nbsp;Mohammed Tag-Adeen,&nbsp;Ahlam Sabra,&nbsp;Samer A El-Sawy,&nbsp;Marwa Ahmed Mahmoud,&nbsp;Saeda Mohamed Abd Elwahab,&nbsp;Mohammed Wahman,&nbsp;Mohammed H Hassan","doi":"10.5114/ceh.2023.125978","DOIUrl":"https://doi.org/10.5114/ceh.2023.125978","url":null,"abstract":"<p><strong>Aim of the study: </strong>To evaluate the role of MIF gene polymorphism rs755622 G>C in occurrence and progression of hepatocellular carcinoma (HCC) among a cohort of Egyptian patients.</p><p><strong>Material and methods: </strong>This case-control study was conducted on 50 patients with HCC after chronic viral hepatitis and 50 healthy volunteers, recruited between July 2021 and January 2022. All patients with HCC were evaluated for severity of liver disease using a Child-Pugh score, and TNM and BCLC scoring systems. MIF 173 G>C (rs755622) single nucleotide polymorphism was performed for all participants by polymerase chain reaction using restriction fragment length polymorphism technique (RFLP-PCR).</p><p><strong>Results: </strong>Overall results showed significantly higher frequencies of GG (wild homozygous genotype) and mutant heterozygous genotype GC and G allele (OR = 6.303, 95% CI: 3.374-11.775) among patients with HCC compared to the control group (<i>p</i> = 0.001) for all. Also, significantly higher frequency of genotype GG was detected among patients with advanced Child scores (B and C) (<i>p</i> = 0.039) and TNM stages (III and IV) (<i>p</i> = 0.013). There was significantly higher frequency of the G allele among patients with multiple hepatic focal lesions compared to those with a single focal lesion (<i>p</i> = 0.01).</p><p><strong>Conclusions: </strong>An obvious role of MIF (rs755622) gene polymorphism could have an important role in susceptibility and progression of HCC among patients with chronic viral hepatitis induced liver cirrhosis.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"46-56"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/13/bb/CEH-9-50365.PMC10090993.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigation of liver fibrosis with serum biochemical parameters before treatment with direct-acting antivirals, at the end of treatment, and in the first and third year after treatment in patients with chronic hepatitis C.","authors":"Mediha Bozkurt,&nbsp;Esra Zerdali,&nbsp;Filiz Pehlivanoğlu","doi":"10.5114/ceh.2023.125917","DOIUrl":"https://doi.org/10.5114/ceh.2023.125917","url":null,"abstract":"<p><strong>Aim of the study: </strong>In the treatment of chronic hepatitis C, the need for non-invasive methods, other than invasive methods, is increasing for the detection of fibrosis before and after treatment. In our study, we aimed to determine the changes in histological response with post-treatment biochemical scoring in patients treated with direct-acting antivirals.</p><p><strong>Material and methods: </strong>Between June 1, 2016, and January 1, 2020, 125 patients followed up with a diagnosis of chronic hepatitis C, who presented to Haseki Training and Research Hospital, were enrolled in the study. Scores of APRI, Fibro Q, Fibrosis-4 (FIB-4) index, Doha score, Fibro alpha, and fibrosis-cirrhosis index were used to evaluate the liver fibrosis of the patients with examinations before treatment, at the end of treatment and at the 12^th week, first year, and third year after treatment. The study was conducted as a retrospective observational case series.</p><p><strong>Results: </strong>One hundred twenty-five patients were enrolled in the study. The mean age was 55.5 ±15.9 years. Patients were divided into two groups according to their baseline FIB-4 values: cirrhotic/noncirrhotic. Seven (5.6%) patients had compensated cirrhosis; there were no decompensated cirrhotic patients. There was a statistically significant decrease in scores of APRI, FIB-4, Fibro Q, and Doha score calculated during the end-of-treatment three-year follow-up period.</p><p><strong>Conclusions: </strong>It was shown that serum fibrosis scores, such as APRI, FIB-4, Fibro Q, and Doha score, could be used to detect fibrosis before treatment and to follow histological improvement after treatment with direct-acting antivirals (DAA) in chronic hepatitis C patients.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"21-27"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e4/76/CEH-9-50350.PMC10090997.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DAPS score - a novel score for prediction of significant fibrosis in incidentally detected asymptomatic hepatitis B subjects.","authors":"Sridhar Sundaram,&nbsp;Harish Darak,&nbsp;Sanjay Kumar,&nbsp;Suprabhat Giri,&nbsp;Shobna Bhatia","doi":"10.5114/ceh.2023.124518","DOIUrl":"https://doi.org/10.5114/ceh.2023.124518","url":null,"abstract":"<p><strong>Aim of the study: </strong>Significant fibrosis is an indication for treatment in hepatitis B patients with normal transaminase levels. The present study was aimed at analyzing the factors associated with significant fibrosis in incidentally detected asymptomatic hepatitis B subjects (IDAHS) and developing a model for fibrosis prediction for use in low-resource settings.</p><p><strong>Material and methods: </strong>This is a single-center retrospective analysis of data on IDAHS who had undergone FibroScan. The variables associated with significant fibrosis in the derivation cohort were subjected to multivariate analysis by logistic regression. The model was applied to the validation cohort for fibrosis prediction.</p><p><strong>Results: </strong>A total of 299 patients (mean age: 42.6 years, males: 63.2%) were included in the model derivation. Significant fibrosis was found in 27.4% (82/299) of the patients and 16.8% (30/178) of those with normal transaminase. On multivariate analysis, age, lower platelet count, and presence of diabetes were associated with fibrosis. Serum glutamic pyruvic transaminase (SGPT) was included in the model as it was nearing towards in multivariate analysis. The DAPS (diabetes, age, platelet count, SGPT) score was proposed with equal weightage to each variable. Based on the cumulative score, patients were categorized as having low risk (DAPS score 0-2) or high risk (DAPS score 3-4). The specificity of the model in derivation and validation cohorts was 98.2% and 97.6%, respectively, while the accuracy was 83.6% and 80%, respectively.</p><p><strong>Conclusions: </strong>Approximately 17% of IDAHS with normal transaminase have significant fibrosis. The DAPS score can be used easily as a bedside tool for assessment of significant fibrosis in IDAHS with excellent specificity.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"9-13"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d8/18/CEH-9-50017.PMC10090992.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9686905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Serum copeptin is associated with major complications of liver cirrhosis and spontaneous bacterial peritonitis.","authors":"Ahmed Abudeif,&nbsp;Marwa S Hashim,&nbsp;Nesma M Ahmed,&nbsp;Ahmed Othman Ahmed","doi":"10.5114/ceh.2023.125970","DOIUrl":"https://doi.org/10.5114/ceh.2023.125970","url":null,"abstract":"<p><strong>Aim of the study: </strong>We aimed to investigate the possible association between serum copeptin and complications of liver cirrhosis, including its potential role as a stress biomarker in spontaneous bacterial peritonitis (SBP).</p><p><strong>Material and methods: </strong>This cross-sectional study included 89 cirrhotic ascitic patients (37 with SBP and 52 without SBP) admitted to Sohag University Hospitals, Egypt, between June 2021 and February 2022. Serum copeptin was measured in all patients, and its association with SBP and other complications of liver cirrhosis was investigated.</p><p><strong>Results: </strong>Serum copeptin was significantly elevated in patients with SBP compared to those without SBP (<i>p</i> = 0.032) and significantly correlated with ascitic fluid study parameters, systemic inflammatory markers, and liver, renal, and circulatory functions. Serum copeptin and C-reactive protein (CRP) were independent risk factors for the presence of SBP. Serum copeptin detects SBP at a cut-off value of 9 pmol/l, with sensitivity and specificity of 73% and 64%, respectively. Serum copeptin was significantly associated with hepatic encephalopathy, gastrointestinal bleeding, hepatorenal syndrome, and larger amounts of ascites.</p><p><strong>Conclusions: </strong>Serum copeptin is an independent risk factor for the presence of SBP and significantly increased in patients presented with major complications of liver cirrhosis, demonstrating its ability to reflect circulatory dysfunction and systemic inflammation.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"71-78"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/01/b3/CEH-9-50364.PMC10090990.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is the extent of functional liver remnant increase truly \"functional\"? A single-institution case series of patients with Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS).","authors":"Kai Siang Chan,&nbsp;Vishal G Shelat,&nbsp;Hsien Min Low,&nbsp;Jee Keem Low","doi":"10.5114/ceh.2023.124476","DOIUrl":"https://doi.org/10.5114/ceh.2023.124476","url":null,"abstract":"<p><strong>Aim of the study: </strong>Associating Liver Partition and Portal vein ligation for Staged hepatectomy (ALPPS) aims to induce rapid hypertrophy of the future liver remnant (FLR) to reduce the risk of post-hepatectomy liver failure (PHLF). However, volumetric increase does not correspond to functional increase. This is a novel study which aims to compare the increase in standardized FLR (sFLR) vs. indocyanine green retention at 15 minutes (ICG-R15).</p><p><strong>Material and methods: </strong>This is a retrospective case series of patients who underwent ALPPS between May 2015 and January 2022. Primary outcomes were sFLR and ICG-R15. Secondary outcomes were incidence of PHLF, morbidity, recurrence, overall survival (OS) and disease-free survival (DFS).</p><p><strong>Results: </strong>There were 10 patients with median age of 60.5 years (range 29-69). Most patients had adenocarcinoma secondary to colorectal origin (80%). There were 7 patients who received neoadjuvant chemotherapy [median 6 cycles (range 5-9)]. Median size of the primary tumour was 5.0 cm (range 2.0-7.0 cm). There was a significant increase in median ICG-R15 after stage 1 ALPPS (8.8% vs. 10.2%, <i>p</i> = 0.024) and increase in median sFLR after stage 1 ALPPS (34.4% vs. 53.0%, <i>p</i> = 0.012). Linear regression showed no significant correlation between sFLR increase and ICG-R15 (B = 0.26, 95% CI: -0.82, 1.34, <i>p</i> = 0.565). One patient had PHLF. Median time to local recurrence and metastatic recurrence was 14.4 months (range 6.9-21.9) and 7.5 months (range 6.9-17.3) respectively. OS and DFS were 50% and 40% respectively.</p><p><strong>Conclusions: </strong>No significant relationship was observed between ICG-R15 and sFLR. Volume increase may overestimate the functional increase following ALPPS. Larger studies are needed to validate our findings.</p>","PeriodicalId":10281,"journal":{"name":"Clinical and Experimental Hepatology","volume":"9 1","pages":"28-36"},"PeriodicalIF":1.5,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/10/0a/CEH-9-50004.PMC10090996.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9317882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}